Patient Characteristics at Time of Dosimetric Assessment with 177Lu-Pentixather
| Previous treatment | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient no. | Sex | Age (y) | Weight (kg) | Height (cm) | eGFR | Disease | Since (mo) | C | R | Auto | Allo |
| 1 | M | 61 | 60 | 158 | 99 | MM | 18 | x | 1 | ||
| 2 | F | 66 | 64 | 163 | 100 | MM | 54 | x | 3 | ||
| 3 | F | 53 | 74 | 165 | 54 | MM | 123 | x | 3 | ||
| 4 | M | 65 | 93 | 192 | 46 | MM | 101 | x | 2 | ||
| 5 | M | 74 | 60 | 173 | 54 | MM | 22 | x | x | 2 | |
| 6 | M | 71 | 80 | 175 | 79 | MM | 77 | x | x | 2 | |
| 7 | F | 66 | 60 | 166 | 40 | MM | 138 | x | x | 1 | |
| 8 | F | 57 | 104 | 157 | 96 | MM | 49 | x | x | 1 | |
| 9 | M | 59 | 77 | 172 | 50 | MM | 23 | x | x | 2 | |
| 10 | M | 46 | 70 | 183 | 92 | AML | 7 | x | 1 | ||
| 11 | M | 60 | 78 | 182 | 82 | AML | 19 | x | 1 | ||
| 12 | F | 54 | 62 | 168 | 67 | AML | 27 | x | 1 | ||
| 13 | F | 64 | 80 | 163 | 85 | DLBCL | 42 | x | 1 | ||
| 14 | F | 59 | 68 | 172 | 20 | DLBCL | 32 | x | x | 1 | |
| 15 | F | 75 | 75 | 168 | 59 | pre-B ALL | 15 | x | |||
| 16 | F | 50 | 78 | 172 | 54 | TCL | 21 | x | 1 | ||
| 17 | F | 55 | 64 | 160 | 96 | ACC | 46 | x | x | ||
| 18 | M | 55 | 90 | 175 | 92 | ACC | 14 | x | x | ||
| 19 | F | 40 | 52 | 163 | n/a | Thymoma | 37 | x | x | ||
eGFR = Chronic Kidney Disease Epidemiology Collaboration glomerular filtrate rate estimate in mL/min per 1.73 m2; C = chemo; R = irradiation; auto = autologous stem cells; allo = allogeneic stem cells; MM = multiple myeloma; AML = acute myeloid leukemia; DLBCL = diffuse large B-cell lymphoma; pre-B ALL = pre-B acute lymphoblastic leukemia; TCL = T-cell leukemia; ACC = adrenocortical carcinoma; n/a = not available.